Section: Contact Information

First Name : Peter Last Name : de Blank Institution : University Hospitals Rainbow Babies & Children's Medical Center Address 1 : 11100 Euclid Avenue Address 2 : City : Cleveland State/Province/Region : OH Country : US Zip/Postal Code : 44106 Phone Number : 216-844-3345 Alternate Phone Number : 216-844-3212 Email Address : peter.deblank@UHhospitals.org

Section: Project Requirements and Description

Group: Requirements to submit AOI

A comprehensive review of previously published data has been completed. : Yes

The specific aims are clear and focused. : Yes

The investigator has appropriate experience and expertise to develop the concept proposal; if not, has identified a mentor or senior co-investigator. : Yes

The investigator agrees to develop an initial draft of the concept proposal within 6 weeks of approval of the AOI and to finalize the concept proposal within 6 months. : **Yes**

Project Title : The Effect of NF1 Status on Late Outcomes in Adults Survivors of Childhood Cancer

Planned research population (eligibility criteria) :

Survivors within the expansion cohort

Proposed specific aims :

1. Determine the effect of NF1 status on long-term functional outcomes (i.e. psychological distress, learning or memory problems, academic attainment and function, pain) in adult survivors of childhood cancer. Note: this aim would be assessed twice, once in all diagnoses and once in those with astrocytomas.

2. Examine the association between NF1 status and socioeconomic attainment (i.e. marital status, employment, independent living, household income) in adult survivors of childhood cancer. Note: this aim would be assessed twice, once in all diagnoses and once in those with astrocytomas.

Explore the association between NF1 status and chronic health conditions and second malignant neoplasm.

Will the project require non-CCSS funding to complete? : No

If yes, what would be the anticipated source(s) and timeline(s) for securing funding? :

Group: Does this project require contact of CCSS study subjects for:

Additional self-reported information : No

Biological samples : No

Medical record data : No

If yes to any of the above, please briefly describe. :

Group: What CCSS Working Group(s) would likely be involved? (Check all that apply)

Second Malignancy : Secondary Chronic Disease : Secondary Psychology / Neuropsychology : Primary Genetics : Cancer Control : Epidemiology / Biostatistics : Secondary

Section: Outcomes or Correlative Factors

Late mortality : Second Malignancy : Secondary

Group: Health Behaviors

Tobacco : Alcohol : Physical activity : Medical screening : Other : If other, please specify :

Group: Psychosocial

Insurance : Marriage : **Primary** Education : **Primary** Employment : **Primary**

Other : Primary

If other, please specify : household income

Group: Medical Conditions

Hearing/Vision/Speech : **Correlative Factors** Hormonal systems : Heart and vascular : Respiratory : Digestive : Surgical procedures : Brain and nervous system : **Primary** Other : If other, please specify :

Group: Medications

Describe medications :

Group: Psychologic/Quality of Life

BSI-18 : **Primary** SF-36 : **Primary** CCSS-NCQ : **Primary** PTS : **Primary** PTG : **Primary** Other : If other, please specify :

Group: Other

Pregnancy and offspring : Family history : Chronic conditions (CTCAE v3) : **Secondary** Health status :

Group: Demographic

Age : Correlative Factors Race : Correlative Factors Sex : Correlative Factors Other : If other, please specify :

Group: Cancer treatment

Chemotherapy : Correlative Factors Radiation therapy : Correlative Factors Surgery : Correlative Factors

Section: Anticipated Sources of Statistical Support

CCSS Statistical Center : **Yes** Local institutional statistician : If local, please provide the name(s) and contact information of the statistician(s) to be involved. : Will this project utilize CCSS biologic samples? : **No**

If yes, which of the following? :

If other, please explain :

Section: Other General Comments

Other General Comments :

This will be designed as a case-control study matching survivors with NF1 with survivors without NF1 on diagnosis, treatment, age at diagnosis, gender and race.